References and Notes
<A NAME="RD08406ST-1">1</A>
Vale W.
Spiess J.
Rivier J.
Science
1981,
213:
1394
<A NAME="RD08406ST-2">2</A>
Gilligan PJ.
Hartig PR.
Robertson DW.
Zaczek R.
In
Annual Reports in Medicinal Chemistry
Vol. 32:
Bristol JA.
Academic;
San Diego:
1997.
p.1-50
<A NAME="RD08406ST-3">3</A>
Turnbull AV.
Rivier C.
Proc. Soc. Experim. Biol. Med.
1997,
215:
1
<A NAME="RD08406ST-4A">4a</A>
Gutman DA.
Owens MJ.
Nemeroff CB.
Pharmaceut. News
2001,
8:
18
<A NAME="RD08406ST-4B">4b</A>
Heinrichs SC.
Tache Y.
Exp. Opin. Invest. Drugs
2001,
10:
647
<A NAME="RD08406ST-5">5</A>
Neurocrine Biosciences Inc. USA . inventors; PCT Int. Appl., WO0027846.
<A NAME="RD08406ST-6">6</A>
Pfizer Inc. USA . inventors; PCT Int. Appl., WO 01/23389A2.
<A NAME="RD08406ST-7">7</A>
Arvanitis AG.
Beck JP.
Curry MA.
Fitzgerald LW.
Gilligan PJ.
Trainor GL.
Zaczek R.
Bioorg. Med. Chem. Lett.
1999,
9:
967
<A NAME="RD08406ST-8">8</A>
Cope AC.
Hancock E.
J. Am. Chem. Soc.
1942,
64:
1503
<A NAME="RD08406ST-9">9</A>
4-Methoxyphenyl isocyanate was purchased from Sigma-Aldrich.
<A NAME="RD08406ST-10">10</A>
Meth-Cohn O.
Zegui Y.
J. Chem. Soc., Perkin Trans. 1
1998,
423
<A NAME="RD08406ST-11">11</A>
Bianchi M.
Butti A.
Rossi S.
Barzaghi F.
Marcaria V.
Eur. J. Med. Chem. Chim. Ther.
1983,
18:
495
<A NAME="RD08406ST-12">12</A>
Maruyama T.
Kozai S.
Uchida M.
Nucleosides Nucleotides
1999,
18:
661
<A NAME="RD08406ST-13A">13a</A>
Beletskaya IP.
Artamkina GA.
Sergeev AG.
Tetrahedron Lett.
2001,
42:
4381
<A NAME="RD08406ST-13B">13b</A>
Beletskaya IP.
Artamkina GA.
Sergeev AG.
J. Org. Chem. USSR (Engl. Transl.)
2003,
39:
1741
<A NAME="RD08406ST-13C">13c</A>
Beletskaya IP.
Artamkina GA.
Sergeev AG.
Tetrahedron Lett.
2003,
44:
4719
<A NAME="RD08406ST-14">14</A>
Buchwald SL.
Yin J.
J. Am. Chem. Soc.
2002,
124:
6043
<A NAME="RD08406ST-15">15</A>
Buchwald SL.
Harris MC.
J. Org. Chem.
2000,
65:
5327
<A NAME="RD08406ST-16">16</A>
Ferraccioli R.
Carenzi D.
Synthesis
2003,
1383
<A NAME="RD08406ST-17">17</A>
Data for 10: mp 128-129 °C (EtOAc). 1H NMR (400 MHz, CDCl3): δ = 7.22 (d, J = 9.1 Hz, 2 H), 6.80 (d, J = 9.1 Hz, 2 H), 6.70 (br s, 1 H), 6.67 (s, 1 H), 6.36 (br s, 1 H), 4.04 (t,
J = 6.1 Hz, 2 H), 3.75 (s, 3 H), 3.74-3.78 (m, 1 H), 3.46 (t, J = 6.1 Hz, 2 H), 2.44 (s, 3 H), 1.89 (s, 3 H), 1.44-1.50 (m, 4 H), 1.21-1.28 (m, 4 H),
0.83 (t, J = 7.3 Hz, 6 H). 13C NMR (100 MHz, CDCl3): δ = 171.1, 157.1, 156.7, 156.4, 154.2, 152.7, 130.8, 123.2, 118.3, 114.2, 112.4,
91.4, 61.9, 61.7, 41.1, 35.7, 24.3, 20.6, 20.2, 14.2. IR (ATR mode): 1735, 1584, 1510,
1244, 1027, 986, 934, 836 cm-1. HRMS (ES): m/z [MH+] calcd for C25H36ClN4O4: 491.2425; found: 491.2406.
<A NAME="RD08406ST-18">18</A>
The urea 10 (300 mg, 0.61 mmol) and K2CO3 (190 mg, 1.38 mmol) were suspended in dioxane (6.0 mL). Pd2(dba)3 (20 mg, 0.022 mmol, 0.036 equiv) and 2-(dicyclohexylphos-phino)-2′-methylbiphenyl
(20 mg, 0.055 mmol, 0.09 equiv) were added and the reaction vessel was flushed with
Ar and the reaction mixture was heated to reflux for 20 h. Solution yield of the product
1 at this point was 86%. The reaction mixture was then evaporated and partitioned between
EtOAc (10 mL) and 5% aq NaHCO3 (5 mL). The EtOAc layer was then separated and dried over MgSO4 before being filtered and evaporated to give the crude product 1 which was purified by chromatography (hexane-EtOAc, 1:1) to give pure 1 in 58% yield. Data for 1: 1H NMR (400 MHz, CDCl3): δ = 7.63 (dd, J = 2.2, 6.8 Hz, 2 H), 7.00 (dd, J = 2.2, 6.8 Hz, 2 H), 6.25 (s, 1 H), 3.98 (t, J = 5.0 Hz, 2 H), 3.83 (s, 3 H), 3.74 (m, 1 H), 3.38 (t, J = 5.0 Hz, 2 H), 2.44 (s, 3 H), 1.55 (m, 4 H), 1.32 (m, 4 H), 0.92 (t, J = 7.3 Hz, 6 H). 13C NMR (100 MHz, CDCl3): δ = 158.3, 152.0, 151.2, 141.4, 138.3, 127.2, 126.8, 114.4, 106.8, 99.2, 55.7,
55.5, 39.4, 34.7, 34.7, 25.2, 20.0, 14.0. IR (ATR mode): 1712, 1654, 1515, 1246, 1036,
854, 793, 735, 691 cm-1. HRMS (ES): m/z [MH+] calcd for C23H31N4O2: 395.2447; found: 395.2441.